CTOs on the Move

Amplyx Pharmaceuticals

www.amplyx.com

 
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.amplyx.com
  • 3210 Merryfield Row
    San Diego, CA USA 92121-1126
  • Phone: 415.578.3263

Executives

Name Title Contact Details

Funding

Amplyx Pharmaceuticals raised $40.5M on 11/11/2015
Amplyx Pharmaceuticals raised $53M on 05/19/2020

Similar Companies

GE Healthcare Life Sciences

GE Healthcare Life Sciences is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Citius Pharmaceuticals

Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets.

MnPharm

MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.